Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$103.43 USD

103.43
2,347,309

+0.47 (0.46%)

Updated Aug 8, 2025 03:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

Sanara Stock Gains From New US Distribution Deal With ChemoMouthPiece

by Zacks Equity Research

SMTI, along with InfuSystem, inked a U.S. distribution agreement with ChemoMouthpiece. Under the agreement, ChemoMouthpiece's oral cryotherapy device will be distributed in cancer centers.

Zacks Equity Research

Owens & Minor Stock to Gain From New Collaboration With Google Cloud

by Zacks Equity Research

OMI announces partnership with Google Cloud to enhance existing QSight capabilities.

Zacks Equity Research

Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts

by Zacks Equity Research

In the closing of the recent trading day, Boston Scientific (BSX) stood at $82.94, denoting a -0.14% change from the preceding trading day.

Zacks Equity Research

HAE or BSX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HAE vs. BSX: Which Stock Is the Better Value Option?

Urmimala Biswas headshot

Medtronic Keeps Capturing High-Growth Markets: Time to Buy MDT Stock?

by Urmimala Biswas

MDT stock breaking above its 200 and 50-day SMAs can be a piece of good news for investors, signaling an uptrend.

Zacks Equity Research

Should You Continue to Retain OMCL Stock in Your Portfolio Now?

by Zacks Equity Research

Omnicell is well-placed for growth in the upcoming quarters owing to its progress in achieving the Autonomous Pharmacy goal.

Zacks Equity Research

Glaukos Stocks Rides on Strong Product Demand Amid Competition

by Zacks Equity Research

GKOS continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.

Zacks Equity Research

Reasons to Retain ResMed Stock in Your Portfolio for Now

by Zacks Equity Research

Strong demand for RMD's market-leading mask portfolio raises investors' optimism.

Zacks Equity Research

LH Stock Expected to Gain From the Ballad Health Acquisition Deal

by Zacks Equity Research

Labcorp has reached an agreement to purchase select outreach laboratory services from Ballad Health.

Zacks Equity Research

MASI Stock Down Despite New SafetyNet Deal for Neonatal Care

by Zacks Equity Research

The latest adoption of Masimo's SafetyNet is likely to improve the care provided to premature newborns and facilitate their early discharge from the hospital.

Zacks Equity Research

Here's Why You Should Retain PDCO Stock in Your Portfolio for Now

by Zacks Equity Research

Investors remain optimistic about Patterson Companies on the back of its broad product line.

Zacks Equity Research

Will Trinity Biotech Stock Gain From Its Latest Patent Process?

by Zacks Equity Research

TRIB announces updates on its European patented process. The company aims to use this process to improve the functionality of its glucose biosensor in its next-gen CGM technology.

Zacks Equity Research

HSIC Stock Likely to Get a Boost From New Henry Schein One Launches

by Zacks Equity Research

Henry Schein's dental software arm unveils Dentrix Eligibility offerings to elevate the insurance verification process.

Zacks Equity Research

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

by Zacks Equity Research

GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.

Zacks Equity Research

VEEV Stock Up Following the Release of New Features of Veeva Site Connect

by Zacks Equity Research

Veeva Systems' Site Connect is likely to aid the sponsors in reducing trial time and expense.

Zacks Equity Research

CRL Stock May Benefit From New Neuroscience Research Collaboration

by Zacks Equity Research

Charles River's new alliance with Insightec to advance therapeutic development using focused ultrasound in neuroscience.

Zacks Equity Research

Will Paragon 28 Stock Gain From the Latest Product Launch of R3FLEX?

by Zacks Equity Research

FNA recently introduced the R3FLEX Stabilization System, whose design should allow surgeons to restore a patient's soft tissue to a more natural anatomy.

Zacks Equity Research

Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now

by Zacks Equity Research

Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.

Zacks Equity Research

Align Technology Stock Dips on Macroeconomic Issues, FX Headwind

by Zacks Equity Research

ALGN is facing a decline in Invisalign ASPs for comprehensive treatment options. This is resulting in a decline in the company's revenues.

Zacks Equity Research

COO Stock Up 0.4% Following the Launch of New Inserter for Paragard IUD

by Zacks Equity Research

Cooper Companies' latest launch is likely to simplify the insertion process of Paragard IUD, thus making it a more accessible contraceptive choice.

Zacks Equity Research

Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?

by Zacks Equity Research

Here is how Addex Therapeutics Ltd. Sponsored ADR (ADXN) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Zacks Equity Research

Abbott's Lingo CGM System Gains U.S. Availability: Stock to Gain?

by Zacks Equity Research

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.

Zacks Equity Research

Reasons to Retain Revvity Stock in Your Portfolio for Now

by Zacks Equity Research

RVTY's strong product portfolio raises optimism about the stock.

Zacks Equity Research

Boston Scientific (BSX) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Boston Scientific (BSX) closed at $81.37, marking a -0.72% move from the previous day.

Zacks Equity Research

QIAGEN Stock Likely to Gain on Collaboration for APOE Genotyping

by Zacks Equity Research

QGEN collaborates with Eli Lilly to develop a QIAstat-Dx IVD panel for APOE genotyping.